ArticleBlood advances2019

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.

Harry P Erba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.